Adding immunotherapy to platinum-gemcitabine chemotherapy can improve outcomes in patients with advanced urothelial carcinoma, but that may depend on the platinum agent used, data suggest.

In a prospective longitudinal trial, researchers assessed the association between academic readiness and outcomes in patients who received brain tumor treatment in early childhood.

Undergoing medical tattooing can be considered the “end” of the breast cancer journey. While they may need continued follow-up with their oncologist, by addressing the physical appearance of their ...

During the first decade of the Affordable Care Act (ACA), survival and mortality increased among young adults with cancer who were eligible for dependent care e ...

Recently, it has been demonstrated that in B-ALL, distinct developmental states are associated with genomic alterations and clinical characteristics.

Safety results and AE management approaches for talquetamab were reported by oncology nurses practicing at study sites participating in the MonumenTAL-1 studies.

Medical tattooing can help patients with breast cancer rebuild a positive body image after treatment.

Researchers found that patients diagnosed with HCC during 2013-2019 were less likely to die from HCC or from any cause than patients who were diagnosed during 2006-2012.

In the past decade, there have been significant advancements in targeted antibody-based immunotherapies for managing r/r ...

Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

Patients who achieved a pathologic complete response after neoadjuvant therapy had better survival outcomes than patients who received adjuvant therapy.

A liver-first treatment approach in primary and colorectal liver metastases (CRLM) is associated with worse recurrence-free survival (RFS) than primary-first or simultaneous treatment approaches, ...